Chronic Kidney Disease (Chronic Renal Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Chronic Kidney Disease Pipeline Drugs Market Overview
Chronic Kidney Disease (Chronic Renal Failure) is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue, weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol.
The Chronic Kidney Disease pipeline drugs market research report provides comprehensive information on the Chronic Renal Failure targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Chronic Kidney Disease targeted therapeutics development with respective active and dormant or discontinued projects.
Chronic Kidney Disease Pipeline Drugs Market Segmentation by Target
Some of the key targets of the Chronic Kidney Disease pipeline drugs market are Mineralocorticoid Receptor, Nuclear Factor Erythroid 2 Related Factor 2, Apolipoprotein L1, Coagulation Factor XI, Interleukin 6, and Others. Mineralocorticoid Receptor and Nuclear Factor Erythroid 2 Related Factor 2 were the top targets in the Chronic Kidney Disease pipeline drugs market in 2022.
Chronic Kidney Disease Pipeline Drugs Market Analysis, by Target
For more Chronic Kidney Disease pipeline drugs market target insights, download a free report sample
Chronic Kidney Disease Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the Chronic Kidney Disease pipeline drugs market are Mineralocorticoid Receptor Antagonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Apolipoprotein L1 Inhibitor, Coagulation Factor XI Inhibitor, Interleukin 6 Inhibitor, and Others. Mineralocorticoid Receptor Inhibitor and Nuclear Factor Erythroid 2 Related Factor 2 Activator were the top MoAs in the Chronic Kidney Disease pipeline drugs market in 2022t.
Chronic Kidney Disease Pipeline Drugs Market Analysis, by Mechanisms of Action
For more Chronic Kidney Disease pipeline drugs market mechanisms of action insights, download a free report sample
Chronic Kidney Disease Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Chronic Kidney Disease pipeline drugs market are oral, intravenous, subcutaneous, parenteral, topical, inhalational, intraarterial, intraarticular, intralesional, intramuscular, intrathecal, nasogastric, and ophthalmic. The oral RoA led the Chronic Kidney Disease drugs market with the highest number of pipeline products in 2022.
Chronic Kidney Disease Pipeline Drugs Market Analysis, by Routes of Administration
For more Chronic Kidney Disease pipeline drugs market routes of administration insights, download a free report sample
Chronic Kidney Disease Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the Chronic Kidney Disease pipeline drugs market are small molecule, cell therapy, monoclonal antibody, biologic, antisense oligonucleotide, gene therapy, recombinant protein, synthetic peptide, and others. Small molecule accounted for the highest number of Chronic Kidney Disease pipeline drugs in 2022.
Chronic Kidney Disease Pipeline Drugs Market Analysis, by Molecule Types
To know more about the molecule types in the Chronic Kidney Disease pipeline drugs market, download a free report sample
Chronic Kidney Disease Pipeline Drugs Market - Competitive Landscape
Some of the leading companies in the Chronic Kidney Disease Pipeline drugs market are AstraZeneca Plc, Bayer AG, Novo Nordisk AS, Algernon Pharmaceuticals Inc, Angion Biomedica Corp, and Others. AstraZeneca Plc dominated the market in 2022.
Chronic Kidney Disease Pipeline Drugs Market Analysis, by Companies
To know more about the leading Chronic Kidney Disease pipeline drugs market players, download a free report sample
Chronic Kidney Disease Pipeline Drugs Market Report Overview
| Key Targets | Mineralocorticoid Receptor, Nuclear Factor Erythroid 2 Related Factor 2, Apolipoprotein L1, Coagulation Factor XI, Interleukin 6, and Others |
| Key Mechanisms of Action | Mineralocorticoid Receptor Antagonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Apolipoprotein L1 Inhibitor, Coagulation Factor XI Inhibitor, Interleukin 6 Inhibitor, and Others |
| Key Routes of Administration | Oral, Intravenous, Subcutaneous, Parenteral, Topical, Inhalational, Intraarterial, Intraarticular, Intralesional, Intramuscular, Intrathecal, Nasogastric, and Ophthalmic |
| Key Molecule Types | Small Molecule, Cell Therapy, Monoclonal Antibody, Biologic, Antisense Oligonucleotide, Gene Therapy, Recombinant Protein, Synthetic Peptide, and Others |
| Leading Companies | AstraZeneca Plc, Bayer AG, Novo Nordisk AS, Algernon Pharmaceuticals Inc, Angion Biomedica Corp, and Others. |
Scope
- The report provides a snapshot of the global therapeutic landscape for Chronic Kidney Disease (Chronic Renal Failure)
- The report reviews Chronic Kidney Disease (Chronic Renal Failure) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Chronic Kidney Disease (Chronic Renal Failure) targeted therapeutics and enlists all their major and minor projects
- The report assesses Chronic Kidney Disease (Chronic Renal Failure) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews the latest news and deals related to Chronic Kidney Disease (Chronic Renal Failure) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Chronic Kidney Disease (Chronic Renal Failure). Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Algernon Pharmaceuticals Inc
Algomedix Inc
Allena Pharmaceuticals Inc
Anagenics Ltd
Angion Biomedica Corp
Angiotensin Therapeutics Inc
Arch Biopartners Inc
Aria Pharmaceuticals Inc
Aronora Inc
Asahi Kasei Pharma Corp
Ashvattha Therapeutics LLC
AstraZeneca Plc
Bayer AG
BerGenBio ASA
BioAegis Therapeutics Inc
Boehringer Ingelheim International GmbH
Boryung Pharmaceutical Co Ltd
Caladrius Biosciences Inc
Ceptur Therapeutics Inc
Chinook Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp
CinCor Pharma Inc
Cinkate Corp
Coegin Pharma AS
Daiichi Sankyo Co Ltd
DiaMedica Therapeutics Inc
Dimerix Ltd
Dizal (Jiangsu) Pharmaceutical Co Ltd
DJS Antibodies Ltd
DURECT Corp
Eagle Pharmaceuticals Inc
Eli Lilly and Co
Ennovabio
Evopoint Bioscience Co Ltd
Evotec SE
Future Medicine Co Ltd
G&P Bioscience Co Ltd
G3 Pharmaceuticals Inc
Gila Therapeutics Inc
GNI Group Ltd
Goldilocks Therapeutics Inc
Gubra ApS
Haisco Pharmaceutical Group Co Ltd
Hangzhou Metai Pharmaceutical Technology Co Ltd
Helixmith Co Ltd
Hybridize Pharma BV
Icagen Inc
iCELL Biotechnology Co Ltd
INVENT Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Jnana Therapeutics Inc
KBP Biosciences Co Ltd
Kibow Biotech Inc
KidneyCure Ltd
Klotho Therapeutics Inc
Liminal BioSciences Inc
Lung Therapeutics Inc
Maze Therapeutics Inc
MD Healthcare Inc
MedBiome Inc
Meridigen Biotech Co Ltd
Novartis AG
NovMetaPharma Co Ltd
Novo Nordisk AS
Oisin Biotechnologies
Oneness Biotech Co Ltd
OPKO Health Inc
Opsidio LLC
Orgenesis Inc
OrthoTrophix Inc
Pharmaxis Ltd
Pharmicell Co Ltd
Poxel SA
ProKidney LLC
Purespring Therapeutics Ltd
RAGE Biotech Pty Ltd
Reata Pharmaceuticals Inc
Rege Nephro Co Ltd
Reliance Life Sciences Pvt Ltd
Renibus Therapeutics Inc
Resverlogix Corp
Sarfez Pharmaceuticals Inc
Scohia Pharma Inc
Senda Biosciences Inc
Senolytic Therapeutics Inc
Sentien Biotechnologies Inc
Shanghai Pharmaceutical Group Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Suzhou Regend Therapeutics Co Ltd
TagCyx Biotechnologies
Unicocell Biomed Co Ltd
Unicycive Therapeutics Inc
Unicyte AG
Vascular BioSciences
Vertex Pharmaceuticals Inc
VESSL Therapeutics Ltd
Vidasym Inc
Vivazome Therapeutics Pty Ltd
Vivoryon Therapeutics NV
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Chronic Kidney Disease pipeline drugs market?
The key targets of the Chronic Kidney Disease pipeline drugs market are Mineralocorticoid Receptor, Nuclear Factor Erythroid 2 Related Factor 2, Apolipoprotein L1, Coagulation Factor XI, Interleukin 6, and Others.
-
What are the key mechanisms of action of the Chronic Kidney Disease pipeline drugs market?
The key mechanisms of action of the Chronic Kidney Disease pipeline drugs market are Mineralocorticoid Receptor Antagonist, Nuclear Factor Erythroid 2 Related Factor 2 Activator, Apolipoprotein L1 Inhibitor, Coagulation Factor XI Inhibitor, Interleukin 6 Inhibitor, and Others.
-
What are the key routes of administration in the Chronic Kidney Disease pipeline drugs market?
The key routes of administration in the Chronic Kidney Disease pipeline drugs market are oral, intravenous, subcutaneous, parenteral, topical, inhalational, intraarterial, intraarticular, intralesional, intramuscular, intrathecal, nasogastric, and ophthalmic.
-
What are the key molecule types in the Chronic Kidney Disease pipeline drugs market?
The key molecule types in the Chronic Kidney Disease pipeline drugs market are key molecule types are small molecule, cell therapy, monoclonal antibody, biologic, antisense oligonucleotide, gene therapy, recombinant protein, synthetic peptide, and others.
-
Which are the leading companies in the Chronic Kidney Disease pipeline drugs market?
Some of the leading companies in the Chronic Kidney Disease pipeline drugs market are AstraZeneca Plc, Bayer AG, Novo Nordisk AS, Algernon Pharmaceuticals Inc, Angion Biomedica Corp, and Others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Chronic Kidney Disease (Chronic Renal Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Genito Urinary System And Sex Hormones reports